DOCSLIB.ORG

Schedule of Investments (Unaudited) Blackrock Health Sciences Trust II (BMEZ) (Percentages Shown Are Based on Net Assets) September 30, 2020

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Schedule of Investments (Unaudited) Blackrock Health Sciences Trust II (BMEZ) (Percentages Shown Are Based on Net Assets) September 30, 2020 Schedule of Investments (unaudited) BlackRock Health Sciences Trust II (BMEZ) (Percentages shown are based on Net Assets) September 30, 2020 Security Shares Value Security Shares Value Common Stocks Biotechnology (continued) Morphic Holding, Inc. (b) 100,431 $ 2,745,784 Biotechnology — 35.4% (b) (a)(b) Neurocrine Biosciences, Inc. 173,765 16,709,242 Acceleron Pharma, Inc. 314,516 $35,392,486 (b) (b)(c) Nkarta, Inc. 422,882 12,711,833 ADC Therapeutics SA 159,142 5,250,095 (b) (a)(b) ORIC Pharmaceuticals, Inc. 196,430 4,912,714 Agios Pharmaceuticals, Inc. 441,750 15,461,250 (b) (b)(d) Passage Bio, Inc. 190,016 2,491,110 Akeso, Inc. 1,660,000 6,043,315 (b) (b) Prothena Corp. PLC 363,100 3,627,369 Akouos, Inc. 426,721 9,759,109 (b) (b) PTC Therapeutics, Inc. 217,736 10,179,158 Alector, Inc. 408,845 4,307,182 (b) (a)(b) Rapt Therapeutics, Inc. 188,948 6,084,126 Alexion Pharmaceuticals, Inc. 168,926 19,330,202 (a)(b) (a)(b) Regeneron Pharmaceuticals, Inc. 68,020 38,076,236 Allakos, Inc. 212,829 17,334,922 (b) (a)(b) Relay Therapeutics, Inc. 61,429 2,616,261 Alnylam Pharmaceuticals, Inc. 277,448 40,396,429 (b) (b) Retrophin, Inc. 394,674 7,285,682 ALX Oncology Holdings, Inc. 286,427 10,809,755 (b) (a)(b) Revolution Medicines, Inc. 103,258 3,593,378 Amicus Therapeutics, Inc. 446,017 6,297,760 (b) (b) Sage Therapeutics, Inc. 157,700 9,638,624 Annexon, Inc. 183,965 5,561,262 (a)(b) (b) Sarepta Therapeutics, Inc. 72,754 10,216,844 Apellis Pharmaceuticals, Inc. 170,360 5,139,761 (b)(e) (b) Seattle Genetics, Inc. 499,885 97,822,496 Applied Molecular Transport, Inc. 165,609 5,269,678 (b) (b) Seres Therapeutics, Inc. 373,800 10,582,278 Arcutis Biotherapeutics, Inc. 155,075 4,543,698 (b) (a)(b) Stoke Therapeutics, Inc. 103,538 3,467,488 Arena Pharmaceuticals, Inc. 152,180 11,381,542 (b) (a)(b) Taysha Gene Therapies, Inc. 178,700 4,002,880 Argenx SE, ADR 121,001 31,765,183 (b) (b) TCR2 Therapeutics, Inc. 228,499 4,643,100 Arrowhead Pharmaceuticals, Inc. 85,746 3,692,223 (a)(b) (b) Twist Bioscience Corp. 242,154 18,396,439 Avidity Biosciences, Inc. 367,800 10,353,570 (a)(b) (b) United Therapeutics Corp. 59,550 6,014,550 Beam Therapeutics, Inc. 169,779 4,179,959 (a)(b) (b) Vertex Pharmaceuticals, Inc. 122,254 33,267,759 Biohaven Pharmaceutical Holding Co. Ltd. 158,500 10,304,085 (b) (b) Vir Biotechnology, Inc. 132,400 4,545,292 BioMarin Pharmaceutical, Inc. 201,275 15,313,002 (b) (b) Voyager Therapeutics, Inc. 262,830 2,804,396 Blueprint Medicines Corp. 75,909 7,036,764 (b) (b) Zai Lab Ltd., ADR 194,310 16,160,763 CareDx, Inc. 227,093 8,615,908 (b) (b) Zentalis Pharmaceuticals, Inc. 227,113 7,424,324 ChemoCentryx, Inc. 46,630 2,555,324 (b) Constellation Pharmaceuticals, Inc. (b) 66,300 1,343,238 Zymeworks, Inc. 252,147 11,745,007 Deciphera Pharmaceuticals, Inc. (b) 82,195 4,216,604 1,049,078,209 Dicerna Pharmaceuticals, Inc. (b) 402,384 7,238,888 Diversified Financial Services (b) — 1.0% Dyne Therapeutics, Inc. (b) 291,334 5,882,033 ARYA Sciences Acquisition Corp. II 204,554 2,250,094 Eidos Therapeutics, Inc. (b) 120,728 6,100,386 ARYA Sciences Acquisition Corp. III, Class A 324,000 3,473,280 Fate Therapeutics, Inc. (b) 112,925 4,513,612 BCTG Acquisition Corp. 167,744 1,818,345 FibroGen, Inc. (b) 160,848 6,614,070 Deerfield Healthcare Technology Acquisitions Forma Therapeutics Holdings, Inc. (b) 543,025 27,064,366 Corp. 319,040 3,391,395 Fusion Pharmaceuticals, Inc. (b) 436,446 5,246,081 FS Development Corp., Class A 285,217 3,194,430 Galapagos NV, ADR (a)(b) 25,042 3,553,710 Health Sciences Acquisitions Corp. 233,344 2,566,784 Genetron Holdings Ltd. (b) 970,000 11,581,800 Longview Acquisition Corp. 486,550 4,938,483 Genmab A/S (b) 218,365 79,245,862 Panacea Acquisition Corp. 206,640 2,479,680 Genmab A/S, ADR (a)(b) 690,930 25,294,947 Therapeutics Acquisition Corp., Class A 407,000 5,852,660 Global Blood Therapeutics, Inc. (b) 82,931 4,572,815 29,965,151 Grifols SA, Class A 704,064 20,245,444 Health Care Equipment & Supplies — 26.3% Gritstone Oncology, Inc. (b) 197,153 522,455 ABIOMED, Inc. (a)(b) 80,185 22,216,056 Halozyme Therapeutics, Inc. (b) 297,201 7,810,442 Alcon AG (b) 780,009 44,421,513 Humanigen, Inc. (b) 241,224 2,566,623 Baxter International, Inc 624,018 50,183,528 Immunomedics, Inc. (b) 533,084 45,328,133 Cardiovascular Systems, Inc. (b) 168,900 6,646,215 Immunovant, Inc. (b) 256,486 9,025,742 Coloplast A/S, Class B 20,658 3,274,065 Insmed, Inc. (b) 256,527 8,244,778 ConvaTec Group PLC (d) 4,668,285 10,754,324 Intellia Therapeutics, Inc. (b) 147,621 2,934,705 Demant A/S (b) 700,875 21,980,217 Iovance Biotherapeutics, Inc. (b) 429,994 14,155,402 DexCom, Inc. (a)(b) 40,467 16,681,711 Kadmon Holdings, Inc. (b) 1,454,723 5,702,514 Edwards Lifesciences Corp. (a)(b) 281,385 22,460,151 Karyopharm Therapeutics, Inc. (b) 406,215 5,930,739 Envista Holdings Corp. (b) 390,050 9,626,434 Keros Therapeutics, Inc. (b) 212,296 8,188,257 GN Store Nord A/S 631,506 47,575,588 Kodiak Sciences, Inc. (b) 180,183 10,668,635 Haemonetics Corp. (a)(b) 276,008 24,081,698 Krystal Biotech, Inc. (b) 163,538 7,040,311 Hill -Rom Holdings, Inc. (a) 146,385 12,224,611 Kymera Therapeutics, Inc. (b) 271,425 8,769,742 Insulet Corp. (a)(b) 142,744 33,771,803 MacroGenics, Inc. (b) 100,800 2,539,152 Intuitive Surgical, Inc. (a)(b) 74,498 52,859,311 Mersana Therapeutics, Inc. (b) 1,558,929 29,027,258 Kangji Medical Holdings Ltd., (Acquired Mirati Therapeutics, Inc. (a)(b) 54,382 9,030,131 06/22/2020, Cost: $9,047,060) (b)(f) 5,001,419 12,273,935 Molecular Templates, Inc. (b) 203,575 2,223,039 Masimo Corp. (a)(b) 237,283 56,013,025 Momenta Pharmaceuticals, Inc. (b) 167,620 8,796,698 Nevro Corp. (a)(b) 250,151 34,846,034 NuVasive, Inc. (b) 137,340 6,670,604 SCHEDULE OF I NVESTMENTS 1 Schedule of Investments (unaudited) (continued) BlackRock Health Sciences Trust II (BMEZ) (Percentages shown are based on Net Assets) September 30, 2020 Security Shares Value Security Shares Value Health Care Equipment & Supplies (continued) Pharmaceuticals (continued) Penumbra, Inc. (a)(b) 113,661 $ 22,093,425 Chugai Pharmaceutical Co. Ltd. 307,500 $ 13,799,202 ResMed, Inc. (a) 177,227 30,382,025 Eisai Co. Ltd. 133,400 12,183,729 Shenzhen Mindray Bio-Medical Electronics Co. Hansoh Pharmaceutical Group Ltd. (b)(d) 9,306,068 45,484,692 Ltd., Class A 419,520 21,574,822 Harmony Biosciences Holdings, Inc. (b) 96,975 3,287,452 Silk Road Medical, Inc. (b) 301,640 20,273,224 Horizon Therapeutics PLC (b) 167,800 13,034,704 Sonova Holding AG, Registered Shares (b) 65,278 16,542,431 Merck KGaA 200,999 29,304,115 STERIS PLC. 139,521 24,582,205 MyoKardia, Inc. (b) 37,465 5,107,603 Straumann Holding AG, Registered Shares 33,816 34,208,310 Nektar Therapeutics (a)(b) 354,718 5,884,772 Tandem Diabetes Care, Inc. (a)(b) 256,174 29,075,749 Ocumension Therapeutics, (Acquired Teleflex, Inc. (a) 144,275 49,114,096 07/06/2020, Cost: $1,489,361) (b)(d)(f) 779,500 2,282,001 Varian Medical Systems, Inc. (b)(e) 241,899 41,606,628 PMV Pharmaceuticals, Inc. (b) 484,687 17,206,388 Venus MedTech Hangzhou, Inc., Class H (b)(d) 181,000 1,931,894 Relmada Therapeutics, Inc. (b) 262,500 9,875,250 779,945,632 Royalty Pharma PLC, Class A 142,470 5,993,713 Health Care Providers & Services — 11.8% UCB SA 390,226 44,319,388 (b) Addus HomeCare Corp. (b) 45,200 4,271,852 WaVe Life Sciences Ltd. 269,300 2,286,357 Amedisys, Inc. (a)(b) 230,923 54,597,125 226,005,386 Amplifon SpA (b) 646,544 23,120,663 Centene Corp. (a)(b) 359,854 20,990,284 Total Common Stocks — 94.4% Chemed Corp. 24,300 11,672,505 (Cost: $2,106,134,937) 2,796,967,793 Encompass Health Corp. (a) 415,607 27,006,143 Par Humana, Inc. (a) 81,306 33,651,740 (000) Jinxin Fertility Group Ltd. (d) 19,509,100 24,755,615 LHC Group, Inc. (a)(b) 247,591 52,627,943 Corporate Bonds (b) Oak Street Health, Inc. 47,017 2,512,589 Biotechnology — 0.1% Oak Street Health Inc., (Acquired 03/04/2020, (f) Kronos Bio, Inc, (Acquired: 08/20/2020, Cost: Cost: $19,349,483) 1,840,247 94,928,118 $4,591,000), 0.00%, 02/14/22 (f)(g)(h) $ 4,591 4,591,000 350,134,577 Health Care Technology (b) — 2.3% Total Corporate Bonds — 0.1% American Well Corp., Class A (c) 668,554 19,815,941 (Cost: $4,591,000) 4,591,000 GoodRx Holdings, Inc., Class A 69,209 3,848,020 Shares Livongo Health, Inc.
Load more

Recommended publications
  • Fund Holdings
    Wilmington International Fund as of 7/31/2021 (Portfolio composition is subject to change) ISSUER NAME % OF ASSETS ISHARES MSCI CANADA ETF 3.48% TAIWAN SEMICONDUCTOR MANUFACTURING CO LTD 2.61% DREYFUS GOVT CASH MGMT-I 1.83% SAMSUNG ELECTRONICS CO LTD 1.79% SPDR S&P GLOBAL NATURAL RESOURCES ETF 1.67% MSCI INDIA FUTURE SEP21 1.58% TENCENT HOLDINGS LTD 1.39% ASML HOLDING NV 1.29% DSV PANALPINA A/S 0.99% HDFC BANK LTD 0.86% AIA GROUP LTD 0.86% ALIBABA GROUP HOLDING LTD 0.82% TECHTRONIC INDUSTRIES CO LTD 0.79% JAMES HARDIE INDUSTRIES PLC 0.78% DREYFUS GOVT CASH MGMT-I 0.75% INFINEON TECHNOLOGIES AG 0.74% SIKA AG 0.72% NOVO NORDISK A/S 0.71% BHP GROUP LTD 0.69% PARTNERS GROUP HOLDING AG 0.65% NAVER CORP 0.61% HUTCHMED CHINA LTD 0.59% LVMH MOET HENNESSY LOUIS VUITTON SE 0.59% TOYOTA MOTOR CORP 0.59% HEXAGON AB 0.57% SAP SE 0.57% SK MATERIALS CO LTD 0.55% MEDIATEK INC 0.55% ADIDAS AG 0.54% ZALANDO SE 0.54% RIO TINTO LTD 0.52% MERIDA INDUSTRY CO LTD 0.52% HITACHI LTD 0.51% CSL LTD 0.51% SONY GROUP CORP 0.50% ATLAS COPCO AB 0.49% DASSAULT SYSTEMES SE 0.49% OVERSEA-CHINESE BANKING CORP LTD 0.49% KINGSPAN GROUP PLC 0.48% L'OREAL SA 0.48% ASSA ABLOY AB 0.46% JD.COM INC 0.46% RESMED INC 0.44% COLOPLAST A/S 0.44% CRODA INTERNATIONAL PLC 0.41% AUSTRALIA & NEW ZEALAND BANKING GROUP LTD 0.41% STRAUMANN HOLDING AG 0.41% AMBU A/S 0.40% LG CHEM LTD 0.40% LVMH MOET HENNESSY LOUIS VUITTON SE 0.39% SOFTBANK GROUP CORP 0.39% NOVARTIS AG 0.38% HONDA MOTOR CO LTD 0.37% TOMRA SYSTEMS ASA 0.37% IMCD NV 0.37% HONG KONG EXCHANGES & CLEARING LTD 0.36% AGC INC 0.36% ADYEN
    [Show full text]
  • Sample of Current Attendees
    SAMPLE OF CURRENT ATTENDEES TITLE COMPANY Sr Mgr Global Meetings Mgmt Amgen Prin Tradeshow Spec Boston Scientific Events Mgr PR Medical Events Sr Buyer Pharma Ops ITA Group Travel Services Supv Grifols Asia Pacific Pte Ltd Compliance Specialist GCO Spend Jouney Lead Global Mtgs Travel Events UCB Category Project Specialist Roche Events & Travel Mgr Teva Brasil Mgr Event Mgmt Bayer Congress Mgr MediCongress Services Global Events Mgmt Sr Assoc Amgen Assoc Dir Congresses & Events MSD Internal Event Mgr Gilead Sourcing Mgr BMS Dir Sourcing Meeting Alliance Custoerm Srvs Meetings Mgr Eli Lilly & Company Sr Congress Mgr Novartis Pharmaceuticals Sourcing Mgr BCD Meetings & Events Sr Buyer Meetings & Incentives Worldwide Sourcing Mgr American Express GBT Acct Mgr Venue Sourcing Ashfield Meetings & Events Mtg Planner AbbVie Sr Sourcing Mgr CWT Dir Sourcing Planning Partners International Meetings Mgr ACOG Meeting Mgr Pfizer Canada Global Event Lead Astellas Meeting & Events Sanofi Events Specialist Cook Medical Meetings & Events Mgr Pfizer Spain Pfizer Spain Sr Mgr Hotel Procurement Meetings & Incentives WorldWide Inc Event Planner SFU BCcampus Mgr Global Strategic Mtg Mgmt Teva Pharmaceuticals Global Mtgs & Events Virtual Mtgs Specialist AstraZeneca Global Congress Strategy Lead MSD Assoc Dir Congresses & Events Alnylam Pharmaceuticals Event Planner AbbVie Institutional & Scientific Events Coordr Almirall Congress Mgr AO Spine Sr Meeting Planner Medtronic Mgr Global Mtgs Mgmt Alnylam Pharmaceuticals Meeting Planner AbbVie Global Audit Meetings
    [Show full text]
  • View State-Of-The-Art Clinical Symposium Disclosures
    Planning Committee Members The following Planning Committee members have no relevant financial relationship(s) with ineligible companies to disclose. Mastering E/M Changes for 2021 • Antanya Chung-Gardiner, BSc • Melesia Tillman 2021 Access in Rheumatology Planning Committee • Marcus Snow, MD 2021 Fellow-in-Training Educational Session Planning Committee • Nadia Elias, MD • Tate Johnson, MD • Justin Levinson, MD, MBA • Jean Lin, MD, PhD • Megan Lockwood, MD • Tyler Reese, MD • Zahra Rehman, MD • Didem Saygin, MD • Rachel Wallwork, MD 2021 State-of-the-Art Clinical Symposium Planning Committee • Sobia Hassan, MD • Aman Kugasia, MD • Jeanie Lee, MD • Manjari Malkani, MD • Rebecca Manno, MD, MHS The following Planning Committee members have relevant financial relationship(s) with ineligible companies to disclose. 2021 Access in Rheumatology Planning Committee • Christopher Phillips, MD - Pfizer (Self): 5 2021 Fellow-in-Training Educational Session Planning Committee • Mary Mamut, DO - Bendcare (Self): 8 2021 State-of-the-Art Clinical Symposium Planning Committee • Rohit Aggarwal, MD, MS - AbbVie, Amgen, , Genzyme, , Novartis, Roche, Sandoz, UCB (Self): 1, 5, 2; AdMIRx, Inc. / Now Q-32 (Self): 5, 2; Alexion (Self): 5; Argenx (Self): 5; AstraZeneca (Self): 5; Boehringer Ingelheim (BI) (Self): 5; Bristol-Myers Squibb(BMS) (Self): 5, 2; Corbus (Self): 5; CSL Behring (Self): 1, 5; EMD Serono (Self): 5, 2; Genentech (Self): 2; Janssen (Self): 5; Kezar (Self): 5; Kyverna (Self): 5; Mallinckrodt (Self): 1, 2; Octapharma (Self): 1, 5; Orphazyme (Self): 1; Pfizer (Self): 5, 2; Scipher Medicine: 5 • Narender Annapureddy, MD, MS - Medpage (Self): 1, Expert Reviewers for the ACR Reading Room section of MedPage Today. • Lianne Gensler, MD - AbbVie (Self): 1, 5; Eli Lilly (Self): 5; Gilead: 5; GSK (Self): 5; Janssen (Self): 5; Novartis (Self): 5; Pfizer (Self): 5, 2; UCB: 5 Faculty The following Faculty members have no relevant financial relationship(s) with ineligible companies to disclose.
    [Show full text]
  • Alcon-20-F-2020.Pdf
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring the shell company report __________ Commission file number: 001-31269 Alcon Inc. (Exact name of Registrant as specified in its charter) N/A (Translation of Registrant's name into English) Switzerland (Jurisdiction of incorporation or organization) Rue Louis-d'Affry 6, 1701 Fribourg, Switzerland (Address of principal executive office) Royce Bedward, Chemin de Blandonnet 8, 1214 Vernier, Geneva, Switzerland; Tel: +41 58 911 20 00; Fax +41 58 911 32 22 (Name, Telephone, Email and/or Facsimile number and Address of Company Contact Person) Securities registered or to be registered pursuant to Section 12(b) of the Act. Title of each class Trading Symbol(s) Name of each exchange on which registered SIX Swiss Exchange Ordinary Shares, nominal value CHF 0.04 per share ALC New York Stock Exchange Securities registered or to be registered pursuant to Section 12(g) of the Act. None Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act.
    [Show full text]
  • Pushing the Limits: Being Innovative in a Regulated Industry
    ISPE Boston Area Chapter Presents: Pushing the Limits: Being Innovative in a Regulated Industry Thursday, November 15, 2018 5:30 pm to 8:30 pm Alnylam 300 Third Street THANK YOU TO OUR PROGRAM SPONSOR Cambridge, MA 02142 EVENT INFORMATION: Join the ISPE Boston Area Chapter for an open forum on innovation. Push your own limits by participating in our pre-program activity with pharma colleagues while enjoying refreshments and a cash bar. Please have valid I. D. ready for a security checkpoint. Walk-ins are still welcome to register onsite. PROGRAM SUMMARY: Innovation comes in many forms ranging from scientific breakthroughs to new technologies and processes. This panel discussion will focus on innovation, and how it impacts the phases of the drug development lifecycle through regulatory compliance. The intent of this discussion is to allow for an interactive look into how innovation can be applied in a regulated field by providing an open forum for the moderator and audience to interact with industry leaders. If you want to better understand how to integrate innovation in your business, or the effects of innovation on your business, this panel will provide much-needed insight. By having people walking the walk of innovation from Development, Engineering, Manufacturing and Regulatory Affairs, we will be able to look to interdependencies, conflict, and synergies of innovative products. Topics will range from technical, personnel, and regulatory decisions needed to incorporate innovation into your business. WHO SHOULD ATTEND: Development, Engineering, Manufacturing, Quality Assurance and Regulatory Affairs personnel. Anybody that wants to better understand how to develop and execute teams when implementing innovative platforms or technologies.
    [Show full text]
  • Human Sequencing Resource with UK Biobank
    January 8, 2018 Regeneron Forms Consortium of Leading Life Sciences Companies to Accelerate Largest Widely-Available 'Big Data' Human Sequencing Resource with UK Biobank By end of 2019, Regeneron plans to sequence the exomes of all 500,000 people within the UK Biobank resource, all with associated health records, creating an unprecedented resource linking human genetic variations to human biology and disease AbbVie, Alnylam Pharmaceuticals, AstraZeneca, Biogen and Pfizer will join Regeneron to co-fund one of the industry's most ambitious 'pre-competitive' research efforts Exome sequencing data and findings will be openly available to other researchers TARRYTOWN, N.Y., Jan. 8, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), along with new collaborators AbbVie, Alnylam Pharmaceuticals, AstraZeneca, Biogen and Pfizer Inc., today announced the formation of a major 'pre-competitive' consortium to fund the generation of genetic exome sequence data from the 500,000 volunteer participants who make up the UK Biobank health resource. The newly announced collaborators will each commit $10 million to enable a dramatic acceleration of sequencing timelines, and additional companies are considering joining the consortium. Regeneron will conduct the sequencing effort. The sequencing data will be paired with detailed, de-identified medical and health records within the UK Biobank resource, including enhanced measures such as brain, heart and body imaging, to create an unparalleled resource for linking human genetic variations to human biology and disease. It was originally planned that sequencing of all 500,000 samples in the UK Biobank would be completed by 2022, with the first 50,000 people sequenced during 2017 with funding from Regeneron and GlaxoSmithKline.
    [Show full text]
  • Cell and Gene Therapy Gathers Pace
    Next-generation therapeutics: cell and gene therapy gathers pace At one of its most exciting phases of growth, the cell and gene therapy market has gained momentum in dealmaking, product sales and big Brain light/Alamy Stock Photo Stock Brain light/Alamy pharma interest, all of which are analyzed in this feature. feature Paul Verdin and Lisa Urquhart Therapeutic approaches employing whole cells are not new—for is substantial ongoing work in oncology, the majority of programs example, techniques based on cultured autologous epidermal cells (65%) across the combined pipeline are in non-oncology indications. for burn treatment and chondrocytes for knee cartilage repair have The value picture reveals a similar overall distribution—indications been available for more than a decade. Gene therapy and other gene outside oncology account for 76% of the 2024 forecasted sales transcription and translation-targeted approaches such as RNA inter- value, and only three oncology indications are included in the top ference (RNAi) are a much more recent addition to the therapeutic 20 indications by 2024 forecast sales (Fig. 2). The top 20 list reveals a arsenal, and coupled with the high-profile arrival of chimeric antigen wide variety of indications, including SMA, amyloidosis, hemophilia receptor (CAR)-T cells are ushering in a new era for cell-based and A and B, sickle cell disease, Huntington’s disease and amyotrophic gene-based medicine. lateral sclerosis. Logically, nucleic acid approaches are on the whole These groundbreaking scientific advances have also brought with focused on those diseases with a clearer genetic basis, whereas cell them intense debate about payment models and affordability, add- therapies are being explored in oncology and those indications with ing fuel to the broader fire raging around drug pricing.
    [Show full text]
  • 2021 Rnai Roundtable
    Glaucienne Diagnosed with AHP (Brazil) Zilebesiran (ALN-AGT), in Development for the Treatment of Hypertension June 30, 2021 © 2021 Alnylam Pharmaceuticals, Inc. 1 Agenda Welcome • Christine Lindenboom – Senior Vice President, Investor Relations & Corporate Communications Introduction • Pushkal Garg, M.D. – Chief Medical Officer Hypertension Background • Elizabeth Ofili, M.D., MPH, FACC; Professor of Medicine (Cardiology), Morehouse School of Medicine Zilebesiran Background and Development Program • Stephen Huang, M.D. – Senior Director, Clinical Research Commercial Outlook • Eric Green – Senior Vice President, Development Programs Q&A Session 2 Reminders Event will run for approximately 60-75 minutes Q&A session at end of presentation • Questions may be submitted at any time via the ‘Ask a Question’ field on the webcast interface Replay, slides and transcript available at www.alnylam.com/capella 3 Alnylam Forward Looking and Disclosure Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including expectations regarding the potential of RNAi therapeutics to reimagine the treatment of hypertension, results from our Phase 1 study of zilebesiran (formerly known as ALN-AGT) supporting further development and the expected timing of additional Phase 1 data readouts, the design and conduct of our KARDIA-1 Phase 2 study of zilebesiran and the expected timing of the initiation of add-on studies, targeting 24 hour blood pressure control with the goal of minimizing CV risk and reducing the risk of organ failure, the potential features of zilebesiran and the potential commercial outlook, our aspiration to become a leading biotech company, and the planned achievement of our “Alnylam P5x25” strategy.
    [Show full text]
  • Rebateable Manufacturers
    Rebateable Labelers – July 2021 Manufacturers are responsible for updating their eligible drugs and pricing with CMS. Montana Healthcare Programs will not pay for an NDC not updated with CMS. Note: Some manufacturers on this list may have some NDCs that are covered and others that are not. Manufacturer ID Manufacturer Name 00002 ELI LILLY AND COMPANY 00003 E.R. SQUIBB & SONS, LLC. 00004 HOFFMANN-LA ROCHE 00006 MERCK & CO., INC. 00007 GLAXOSMITHKLINE 00008 WYETH PHARMACEUTICALS LLC, 00009 PHARMACIA AND UPJOHN COMPANY LLC 00013 PFIZER LABORATORIES DIV PFIZER INC 00015 MEAD JOHNSON AND COMPANY 00023 ALLERGAN INC 00024 SANOFI-AVENTIS, US LLC 00025 PFIZER LABORATORIES DIV PFIZER INC 00026 BAYER HEALTHCARE LLC 00032 ABBVIE INC. 00037 MEDA PHARMACEUTICALS, INC. 00039 SANOFI-AVENTIS, US LLC 00046 WYETH PHARMACEUTICALS INC. 00049 ROERIG 00051 ABBVIE INC 00052 ORGANON USA INC. 00053 CSL BEHRING L.L.C. 00054 HIKMA PHARMACEUTICAL USA, INC. 00056 BRISTOL-MYERS SQUIBB PHARMA CO. 00065 ALCON LABORATORIES, INC. 00068 AVENTIS PHARMACEUTICALS 00069 PFIZER LABORATORIES DIV PFIZER INC 00071 PARKE-DAVIS DIV OF PFIZER 00074 ABBVIE INC 00075 AVENTIS PHARMACEUTICALS, INC. 00078 NOVARTIS 00085 SCHERING CORPORATION 00087 BRISTOL-MYERS SQUIBB COMPANY 00088 AVENTIS PHARMACEUTICALS 00093 TEVA PHARMACEUTICALS USA, INC. 00095 BAUSCH HEALTH US, LLC Page 1 of 19 Manufacturer ID Manufacturer Name 00096 PERSON & COVEY, INC. 00113 L. PERRIGO COMPANY 00115 IMPAX GENERICS 00116 XTTRIUM LABORATORIES, INC. 00121 PHARMACEUTICAL ASSOCIATES, INC. 00131 UCB, INC. 00132 C B FLEET COMPANY INC 00143 HIKMA PHARMACEUTICAL USA, INC. 00145 STIEFEL LABORATORIES, INC, 00168 E FOUGERA AND CO. 00169 NOVO NORDISK, INC. 00172 TEVA PHARMACEUTICALS USA, INC 00173 GLAXOSMITHKLINE 00178 MISSION PHARMACAL COMPANY 00185 EON LABS, INC.
    [Show full text]
  • Corporate Governance Report
    Corporate Governance Report 30 June 2009 Board of Directors Executive Board Contents Preliminary remarks 3 1. Board of Directors 4 1.1 Members of the Board of Directors 4 1.2 Professional background and other activities and functions 4 1.3 Cross-involvement 7 1.4 Internal organisational structure 8 2. Executive Board 10 2.1 Members of the Executive Board 10 2.2 Professional background and other activities and functions 11 General Organisation of Nestlé S.A. 15 Situation at 30 June 2009 © 2009, Nestlé S.A., Cham and Vevey (Switzerland) Concept Nestlé S.A., Group Governance Design Nestec Ltd., SGDU, Corporate Identity & Design 2 Nestlé Corporate Governance Report June 2009 Preliminary remarks Nestlé S.A. publishes a full Corporate Governance Report, Contact for Media: including a separate Compensation Report, which Nestlé S.A. forms an integral part of the annual Management Report. Corporate Media Relations We therewith comply with the requirements of the Avenue Nestlé 55 SIX Swiss Exchange (SIX) and its Corporate Governance CH - 1800 Vevey (Switzerland) Directive. tel. +41 (0)21 924 22 00 The present document is a partial update of the fax +41 (0)21 922 63 34 Nestlé Corporate Governance Report 2008, indicating e-mail: [email protected] changes occurred on the Board of Directors and the Executive Board up to 30 June 2009. Contact for Investors: The annual Management Report is available Nestlé S.A. on-line as a PDF file at http://www.nestle.com in English, Investor Relations French and German. Copies can be ordered at: Avenue Nestlé 55 http://www.nestle.com/Media_Center/Order.
    [Show full text]
  • Current Sustaining Member Companies
    CURRENT SUSTAINING MEMBER COMPANIES MEMBER FOR OVER: 10 Years 25 Years 50 Years Member Since (alphabetical order) 1976 3M Medical Solutions Division 2018 Coherus Biosciences 2019 Ipsen Biopharmaceuticals, Inc. 2011 Remund Group, LLC 1985 Abbott Laboratories, Inc. 2017 Cook Medical, LLC 2018 IT Cadre 2018 Rigel Pharmaceuticals 2013 AbbVie Inc. 2020 D2 Pharma Consulting, LLC 1989 J & J Health Care Systems, Inc. 2000 Sanofi 2021 Adaptive Biotechnologies 2007 Daiichi Sankyo, Inc. 2014 Jazz Pharmaceuticals Inc. 2020 Seattle Genetics 2017 ACADIA Pharmaceuticals, Inc. 2020 Deciphera Pharmaceuticals, LLC 2007 Karl Storz Endoscopy America 2004 Siemens Medical Solutions 2020 AcelRx Pharmaceuticals, Inc. 2009 Deloitte 2020 Lipogems 2019 SK Life Science, Inc. 2020 Acorda Therapeutics 2020 Dexcom, Inc. 2010 LLC Federal Solutions 2002 Smith & Nephew, Inc. 2019 Aimmune 2020 Drip Drop Hydration 2014 Lovell Government Services LLC 2019 Sobi Inc. 2003 Alcon Laboratories, Inc. 2017 Eagle Pharmaceuticals, Inc. 2014 Mallinckrodt Pharmaceuticals 2013 Stryker Orthopaedics 2019 Alexion Pharmaceuticals, Inc. 2005 Eisai, Inc. 2020 MannKind Corporation 2018 Sun Pharmaceutical 2017 Alkermes, Inc. 2019 electroCore, Inc. 1999 Marketing Assessment, Inc. 1999 Sunovion Pharmaceuticals, Inc. 2019 Alnylam Pharmaceuticals 2010 Endo Pharmaceuticals 2009 Masimo Corporation 2016 Taiho Oncology, Inc. 2019 Altarum Institute 2017 Exelixis 2019 Medical Strategies International, LLC 2015 Takeda Oncology 2020 Amarin Corporation 2016 Express Scripts Federal Pharmacy 2016 Melling Medical 2000 Takeda Pharmaceutical USA, Inc. 1994 AmerisourceBergen 2010 Federal Practitioner 1954 Merck & Co., Inc. 2020 Telemynd 1992 Amgen 2018 Foundation Medicine, Inc. 2002 MerzNorth America 2020 TerSera Therapeutics 2020 Amneal Pharmaceutical 2021 Frontier Technology Inc. (FTI) 2018 Mitsubishi Tanabe Pharma America 1990 Teva 2019 Aptive Resources LLC 2020 Fresenius Medical Care North America 2014 Nationwide Pharmaceutical LLC 2019 The Coalition for Government Procurement 2011 Arbor Pharmaceuticals, LLC 1989 Genentech Inc.
    [Show full text]
  • Annual Report 2015
    Annual Report 2015 — Financial Overview Annual Report 2015 Financial Overview Corporate Governance Report Remuneration Report Report Financial Annual Report 2015 Financial Overview Financial Report Remuneration Report Corporate Governance Report Financial Report Remuneration Report Consolidated Financial Statements Compensation and Performance Overview 2015 100 Consolidated Balance Sheet 4 Compensation-Setting Process 101 Consolidated Income Statement 5 Compensation Components 103 Consolidated Statement of Comprehensive Income 5 Compensation of the Board of Directors 104 Consolidated Cash Flow Statement 6 Compensation of the Executive Committee 106 Consolidated Statement of Changes in Equity 7 Share Ownership of the Members of the Board of Notes to the Consolidated Financial Statements 8 Directors and the Executive Committee 116 Report of the Statutory Auditor 81 Report of the Statutory Auditor 119 Financial Statements of Lonza Group Ltd, Basel Balance Sheet 82 Corporate Governance Report Income Statement 83 Notes to the Financial Statements 84 Group Structure and Shareholders 122 Proposal of the Board of Directors 89 Capital Structure 124 Report of the Statutory Auditor 91 Board of Directors 127 Executive Committee 139 Supplementary Financial Information Compensation, Shareholdings and Loans 143 Investor Information 92 Shareholders’ Participation Rights 143 Statement of Value Added 94 Changes of Control and Defense Measures 144 Free Cash Flow 95 Auditors 145 CORE Results 96 Information Policy and Key Reporting Dates 146 Financial Report
    [Show full text]